CascadiaLabs

08/14/2026

‼️‼️ Important, especially if you're a medspa owner looking for proper sources and two day shipping. Come to CascadiaLabs!

Eli Lilly is offering expanded access to retatrutide, its investigational triple hormone receptor agonist that demonstrated substantial weight loss in phase 3 studies, and not all clinicians are happy about the move.

“For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA’s guidance,” a Lilly spokesperson said. “We’ve built an expanded access program that does that and are actively reviewing requests from healthcare providers.” Tap the link to read clinicians views: https://mdsc.pe/4fDkmMF

08/12/2026

Are you a Med Spa Owner? Run a clinic of your own? Don't wanna lose patients to telehealth sites and long, arduous shipping times from your Chinese grey market suppliers?

This is where we, CascadiaLabs, come into the picture.
We keep your business clean and efficient because keeping your medical license is all about being able to provide with solid COAs and safety in mind for patients with a growing interest in peptide therapy.

The FDA regulates drug approval, manufacturing, labeling, and interstate commerce. State
medical boards regulate the practice of medicine. Physicians are ultimately evaluated by
their own licensing authorities based on whether they exercised appropriate clinical
judgment and complied with the applicable standard of care.

That distinction matters.

When physicians evaluate any therapy, the relevant questions are typically:
• Is there a legitimate clinical rationale?
• Has the patient been properly evaluated?
• Have appropriate diagnostics been performed?
• Has informed consent been obtained?
• Is the patient being monitored appropriately?
• Is the treatment decision adequately documented?

Those are the questions that frequently arise in professional liability and medical board
proceedings.

At Cascadia, we believe that product quality and physician diligence should work together.

That is why our platform is built around three core safety protocols:
1. Comprehensive laboratory testing, including molecular purity, sterility, endotoxin,
and heavy metal analysis.
2. Batch tracking and traceability to ensure that testing results correspond to the
specific material being supplied.
3. Supplier qualification and inspection procedures designed to evaluate the reliability
and consistency of our sourcing partners.
Our role is not to practice medicine. That responsibility belongs to the physician.

Sign up with us, enjoy the 2 day shipping, and stay for the incredible deals we are running for GLP-1s.

Comment "Peptide" if you are a certified practice owner or physician interested in getting involved with us today.

07/18/2026

For years, conventional wisdom held that skin improvements among patients on GLP-1 medications were a byproduct of weight loss, which reduces inflammation. But doctors are spotting a much more complex reality — and new research supports their observations.

At the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, Pennsylvania, dermatologist Joe K. Tung, MD, MBA, noticed dramatic changes in his patients with psoriasis just starting a GLP-1. Their plaques began “melting away” within 2 days. “That’s too fast for that to be a weight-loss effect,” he said. “The next step for me was just thinking, could this mechanistically be plausible?” More on the findings: https://mdsc.pe/4aPfzF2

07/18/2026

Obesity and diabetes could be the major causes behind the decline in male hormone levels, scientists say

07/16/2026

💡 Med Spa Owners: Are you unknowingly putting your practice at risk?
If you are sourcing peptides from a 503A Pharmacy under the assumption that it's the "safest" regulatory route, there is a massive legal blind spot you need to know about.
The FDA has made it illegal for 503A Pharmacies to compound virtually all peptides. When a peptide isn’t eligible for compounding under Section 503A, purchasing and administering it anyway opens up serious federal, state, and medical board risks for your practice.

🔍 The Legal Reality Every Physician & Med Spa Director Must Ask:
> "Is this peptide actually eligible for compounding under Section 503A?"
> Just because a pharmacy is licensed or federally registered does not mean every peptide they dispense satisfies compounding laws. If you knowingly purchase unlawfully compounded peptides, your practice could face scrutiny regarding:
* Federal Risks: Participation in an unlawful distribution chain, handling misbranded or adulterated drugs, and unlawful interstate commerce.
* Medical Board Considerations: Boards may evaluate if a "reasonably prudent physician" should have known the peptide was ineligible—potentially calling your professional judgment into question.
* Standard of Care: State boards could view the procurement of these products as unprofessional conduct or a departure from the applicable standard of care.
🛡️ Two Different Legal Frameworks: Why Cascadia is the Intelligent Path
How you source matters. Look at how the legal frameworks stack up:
* Scenario A (The 503A Route): If the peptide is ineligible, federal compounding protections do not apply, the legality of the product is questioned, and severe regulatory risks arise.
* Scenario B (Cascadia’s Peptides): We operate under a completely different, transparent legal framework. We make no representations that our products are compounded prescription drugs, we do not invoke Section 503A protections, and we do not claim FDA approval.
By evaluating the legal status of the peptide itself—rather than just relying on the seller's registration—you protect your license, your patients, and your business.
📲 Take Action & Secure Your Practice Today
Don't let regulatory confusion compromise the reputation you’ve built. Let's get your clinic aligned with the safest, most transparent procurement standards.
📥 Send me a direct message today to start your onboarding with Cascadia Labs! I will walk you through our onboarding process, answer your compliance questions, and share our complete legal white paper.
Let's build a future of science, safety, and superior results you can trust.

07/09/2026

About one in nine Americans take a GLP-1 medication for weight loss, results from a new Gallup poll found—a staggering rise over the past two years as the obesity rate in the U.S. continues to decline from a record high in 2022.
Read more: https://www.forbes.com/sites/zacharyfolk/2026/07/07/11-of-americans-now-take-glp-1-drugs-as-obesity-rate-declines-poll-finds/?utm_source=ForbesMainFacebook&utm_medium=social&utm_campaign=ForbesMainFB
Photo: Michael Siluk/UCG/Universal Images Group via Getty Images

06/30/2026